Moody’s downgrades Senegal to Caa1 amid rising debt concerns
PALO ALTO - 180 Life Sciences Corp. (NASDAQ:ATNF), a micro-cap biotech company with a market capitalization of $5.29 million, announced Tuesday it has secured two new patents for its legacy intellectual property portfolio while the company continues its pivot to the global iGaming sector.
The United States Patent and Trademark Office granted U.S. Patent No. 12,325,744 B2 for methods to prevent or reduce post-operative cognitive decline. This patent, owned by The Kennedy Trust and licensed to 180 Life Sciences, covers treatments for cognitive impairment following planned inflammatory triggers such as surgery or chemotherapy.
Additionally, the Canadian Intellectual Property Office issued a Notice of Allowance for a patent application covering treatment of localized fibrotic disorders using an IL-33 antagonist. This patent, owned solely by 180 Life Sciences, applies to conditions including Dupuytren’s Disease and Frozen Shoulder.
"These two new patent milestones demonstrate the continued productivity and relevance of 180’s legacy IP platform," said Blair Jordan, CEO of 180 Life Sciences, in the press release. According to InvestingPro data, the company’s stock has declined nearly 50% over the past six months, trading at $0.93, though it maintains a FAIR overall financial health rating.
The biotech company is currently transitioning to focus on the global iGaming sector through its recently acquired Technology Gaming Platform. The company stated it aims to maximize shareholder value through potential future partnering, licensing, or strategic transactions related to its legacy intellectual property assets. InvestingPro analysis reveals 7 additional key insights about the company’s financial position and market performance, available to subscribers.
The company continues to engage in strategic discussions regarding the advancement of these and other legacy assets, though no definitive transactions have been agreed upon to date.
In other recent news, 180 Life Sciences Corp. is making notable strides in several areas. The company announced a significant development with the receipt of a Notice of Allowance from the United States Patent and Trademark Office for a method aimed at reducing Post-Operative Cognitive Dysfunction. This potential patent could play a crucial role in addressing a common post-surgery complication among elderly patients. Additionally, 180 Life Sciences has entered into an agreement to repurchase and cancel approximately 23.1% of its outstanding shares, a move intended to reduce shareholder dilution and streamline its capital structure. This agreement involves Elray Resources, Inc. and Luxor Capital, LLC, with a payment of $1 million structured to facilitate the buyback. The company is also advancing its strategic shift towards the iGaming sector, leveraging its Technology Gaming Platform to explore potential acquisitions in online casino and related entertainment businesses. CEO Blair Jordan has highlighted these efforts as part of the company’s broader strategy to enhance stockholder value. Furthermore, 180 Life Sciences has scheduled its 2025 Annual Meeting of Shareholders for July 24, with details to be provided in an upcoming proxy statement. These developments reflect the company’s ongoing transformation and strategic initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.